(Total Views: 388)
Posted On: 11/27/2019 3:17:11 PM
Post# of 72444
You would think we could find a partner who would put up $15 million and fund the phase 3 (another $15-30 million) trial for a 75% cut of B-OM.
That's half what Galera received upfront and infinitely better than self-funding. If we double the share count to fund B-OM you're also indirectly selling half of B-UC and Kevetrin.
That's half what Galera received upfront and infinitely better than self-funding. If we double the share count to fund B-OM you're also indirectly selling half of B-UC and Kevetrin.
(0)
(0)
